| Entry Price | ₹350Starting Price |
|---|---|
| Market Cap | ₹62,903 CrLarge Cap |
| Revenue TTM | ₹14,712 CrAnnual Operating |
| RSI | 42.3Neutral Zone |
Key highlights
- First pharmaceutical company in India to introduce semaglutide in a single-shot pre-filled syringe format
- Competitive entry pricing starting at INR 350 per unit to enhance patient accessibility
- DCGI approval secured for management of Type 2 diabetes mellitus and obesity as adjunct to diet and exercise
- Strategic expansion follows the March 2026 launch of pre-filled disposable and reusable injection pens
- Regulatory approval already received for semaglutide vials which are scheduled for upcoming launch
The Product — What It Is
The newly introduced delivery format features semaglutide in single-shot pre-filled syringes available across multiple dose strengths. This ready-to-use format is specifically designed to provide enhanced convenience and access for patients requiring GLP-1 receptor agonist therapy. The product has received formal approval from the Drugs Controller General of India for two primary indications: the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.
By offering a single-use syringe alternative to multi-dose pens, the company provides healthcare professionals with a versatile tool for initiating treatment in a price-sensitive market.
Commercial Opportunity
- Lowers entry barriers for metabolic treatment with a pricing strategy starting at INR 350
- Captures first-mover advantage in the single-shot pre-filled syringe segment in the Indian market
- Addresses the rising domestic disease burden through multiple drug delivery formats including pens and syringes
- Future portfolio expansion planned with the imminent launch of semaglutide vials for further market penetration
- Strategic positioning as an affordable provider of high-demand chronic therapy medications
Strategic Fit
Alkem Laboratories, the sixth-largest pharmaceutical company in India, is leveraging its established chronic therapy portfolio to dominate the metabolic disorder segment. This launch aligns with the company's focus on high-growth areas including diabetes, cardiology, and dermatology. With 18 state-of-the-art manufacturing facilities and specialized R&D centres across India and the US, Alkem is well-positioned to scale the production of complex generic formulations.
The introduction of multiple semaglutide delivery formats demonstrates a commitment to lifecycle management and brand stickiness as patients transition through different stages of metabolic treatment over their therapy duration.
Industry Context
The Indian pharmaceutical sector is increasingly shifting toward affordable versions of advanced biologic and peptide therapies. Metabolic disorders, particularly Type 2 diabetes and obesity, represent a significant portion of the domestic disease burden, driving consistent demand for innovative GLP-1 analogues. As patent landscapes evolve, domestic leaders are focusing on local manufacturing and innovative delivery systems to challenge international benchmarks.
Alkem's move into the pre-filled syringe segment reflects a broader trend of democratizing access to high-end treatments, which were previously limited by high costs and complex administration protocols in emerging markets.
“Semaglutide has the potential to change how we manage metabolic disorders. With the launch of our pre-filled syringes, we are widening the choice available to doctors and patients, alongside the pen options we have already introduced.”
| Share price | ₹5261 |
|---|---|
| Market capitalisation | ₹62,903.15 Cr |
| Revenue (annual) | ₹14,712.27 Cr |
| Net profit (annual) | ₹2,301.80 Cr |
| Revenue (latest quarter) | ₹3,603.32 Cr-3.57% vs previous quarter |
| Net profit (latest quarter) | ₹236.46 Cr-62.82% vs previous quarter |
| P/E (TTM) | 27.33×Sector 39.69× |
| Promoter holding | 51.2%0.00% QoQ |
| FII holding | 10.15%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Alkem Laboratories Limited announcing the launch of semaglutide in single-shot pre-filled syringes. Market figures from a third-party data provider.
